AUPHNasdaqPharmaceutical PreparationsFiscal year ends December 31
Aurinia Pharmaceuticals Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$16.49−0.02 (-0.12%)
Close on Oct 19, 2026
- Market cap
- $2.20B
- P/E (TTM)
- 7.2
- Dividend yield
- –
Aurinia Pharmaceuticals statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Aurinia Pharmaceuticals | Industry median |
|---|---|---|
| Market Cap | $2.19B | $197.05M |
| Enterprise Value | $2.01B | $106.56M |
| PE Ratio | 7.20 | 20.52 |
| PS Ratio | 7.04 | 3.93 |
| PB Ratio | 3.57 | 2.14 |
| P/TBV Ratio | 3.59 | 2.46 |
| P/OCF Ratio | 12.52 | 13.78 |
Enterprise value
| Measure | Aurinia Pharmaceuticals | Industry median |
|---|---|---|
| EV / Sales | 6.47 | 2.69 |
| EV / EBITDA | 11.84 | 14.86 |
| EV / EBIT | 13.36 | 19.00 |
Income (trailing twelve months)
| Measure | Aurinia Pharmaceuticals | Industry median |
|---|---|---|
| Revenue | $311.51M | $57.94M |
| Gross Profit | $281.47M | $90.47M |
| Operating Income | $150.75M | -$21.44M |
| Pretax Income | $160.36M | -$14.45M |
| Net Income | $314.11M | -$22.46M |
| EBITDA | $170.13M | -$16.91M |
| EPS (Diluted) | $2.29 | -$0.83 |
Margins
| Measure | Aurinia Pharmaceuticals | Industry median |
|---|---|---|
| Gross Margin | 90.4% | 52.3% |
| Operating Margin | 48.4% | -44.5% |
| Pretax Margin | 51.5% | -13.0% |
| Profit Margin | 100.8% | -39.2% |
| EBITDA Margin | 54.6% | -31.3% |
Returns
| Measure | Aurinia Pharmaceuticals | Industry median |
|---|---|---|
| Return on Equity (ROE) | 66.1% | -53.1% |
| Return on Assets (ROA) | 48.5% | -41.0% |
| Return on Invested Capital (ROIC) | 42.0% | -32.0% |
| Return on Capital Employed (ROCE) | 21.8% | -37.8% |
Growth
| Measure | Aurinia Pharmaceuticals | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 19.8% | 6.01% |
| Net Income Growth (YoY) | 418.0% | -37.7% |
| EPS Growth (YoY) | 432.6% | -29.2% |
| Revenue Growth (3Y CAGR) | 28.3% | 2.25% |
| Revenue Growth (5Y CAGR) | 41.4% | 6.42% |
Balance sheet
| Measure | Aurinia Pharmaceuticals | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $179.73M | $62.42M |
| Net Cash (Debt) | $179.73M | $15.68M |
| Net Cash Per Share | $1.35 | $0.65 |
| Equity (Book Value) | $614.86M | $48.79M |
| Book Value Per Share | $4.62 | $1.36 |
| Tangible Book Value | $611.49M | $23.06M |
| Working Capital | $441.43M | $75.77M |
Financial position
| Measure | Aurinia Pharmaceuticals | Industry median |
|---|---|---|
| Current Ratio | 5.42 | 3.30 |
| Quick Ratio | 1.80 | 2.39 |
| Interest Coverage | 36.71 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Aurinia Pharmaceuticals | Industry median |
|---|---|---|
| Operating Cash Flow | $175.24M | -$12.35M |
Efficiency
| Measure | Aurinia Pharmaceuticals | Industry median |
|---|---|---|
| Asset Turnover | 0.48 | 0.38 |
| Inventory Turnover | 0.66 | 2.67 |
| Revenue Per Employee | $2.43M | $398.96K |
| Profits Per Employee | $2.45M | -$732.08K |
| Employee Count | 128 | 73 |
Dividends and yields
| Measure | Aurinia Pharmaceuticals | Industry median |
|---|---|---|
| Earnings Yield | 14.3% | -21.2% |
| Buyback Yield | 3.81% | -0.58% |
| Shareholder Yield | 3.81% | 0.00% |
Shares
| Measure | Aurinia Pharmaceuticals | Industry median |
|---|---|---|
| Shares Outstanding | 133,051,000 | 59,128,900 |
| Shares Change (YoY) | -5.38% | 11.1% |
| Shares Change (QoQ) | 1.63% | 0.54% |
| Float | 109,878,000 | 48,744,500 |
| Shares Held by Insiders | 17.4% | 11.8% |
| Shares Held by Institutions | 58.7% | 59.4% |
Taxes
| Measure | Aurinia Pharmaceuticals | Industry median |
|---|---|---|
| Income Tax | -$153.75M | $91.50K |
| Effective Tax Rate | -95.9% | 20.6% |
Scores
| Measure | Aurinia Pharmaceuticals | Industry median |
|---|---|---|
| Graham Number | $15.43 | $17.36 |
| Graham Upside | -6.42% | -45.5% |
| Altman Z-Score | 8.09 | 0.10 |
| Piotroski F-Score | 8 | 4 |
Calculated by StockData from Aurinia Pharmaceuticals's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.